AtriCure (NASDAQ:ATRC) Reaches New 1-Year High – Here’s What Happened

AtriCure, Inc. (NASDAQ:ATRC) reached a new 52-week high on Wednesday . The company traded as high as $60.99 and last traded at $60.9210, with a volume of 76652 shares traded. The stock had previously closed at $58.83.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Zacks Research cut shares of AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday, August 24th. UBS Group reduced their price target on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Citigroup restated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Raymond James Financial set a $52.00 price target on shares of AtriCure in a research report on Tuesday, July 21st. Finally, Piper Sandler increased their price objective on AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, AtriCure currently has an average rating of “Moderate Buy” and an average target price of $53.30.

AtriCure Trading Up 1.7%

The business’s 50-day simple moving average is $45.75 and its 200-day simple moving average is $34.86. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The company has a market capitalization of $3.04 billion, a price-to-earnings ratio of 284.38 and a beta of 1.26.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The company had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. During the same quarter in the previous year, the company posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, research analysts expect that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Sven Wehrwein sold 25,000 shares of the company’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total value of $946,000.00. Following the completion of the sale, the director owned 40,518 shares in the company, valued at $1,533,201.12. This represents a 38.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Vinayak Doraiswamy sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total value of $233,280.00. Following the sale, the insider directly owned 86,511 shares in the company, valued at approximately $3,363,547.68. This represents a 6.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 70,349 shares of company stock worth $3,046,757 over the last ninety days. Insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On AtriCure

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tidal Investments LLC lifted its holdings in AtriCure by 46.2% during the 2nd quarter. Tidal Investments LLC now owns 19,091 shares of the medical device company’s stock valued at $534,000 after purchasing an additional 6,034 shares during the last quarter. WINTON GROUP Ltd bought a new position in shares of AtriCure in the second quarter valued at about $1,002,000. Engineers Gate Manager LP raised its position in shares of AtriCure by 12.3% in the second quarter. Engineers Gate Manager LP now owns 48,160 shares of the medical device company’s stock valued at $1,348,000 after purchasing an additional 5,283 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in shares of AtriCure during the 2nd quarter worth about $46,000. Finally, Allworth Financial LP boosted its holdings in shares of AtriCure by 372.8% during the 2nd quarter. Allworth Financial LP now owns 1,527 shares of the medical device company’s stock worth $43,000 after buying an additional 1,204 shares during the period. 99.11% of the stock is currently owned by institutional investors and hedge funds.

About AtriCure

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.